Live Breaking News & Updates on James salierno

Stay informed with the latest breaking news from James salierno on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in James salierno and stay connected to the pulse of your community

ReShape Lifesciences Inc. to Merge With Obalon Therapeutics, Inc. to Expand Weight Loss Product Offering

ReShape Lifesciences Inc. to Merge With Obalon Therapeutics, Inc. to Expand Weight Loss Product Offering
SAN CLEMENTE, CA / ACCESSWIRE / January 20, 2021 / ReShape Lifesciences Inc. (OTCQB:RSLS), a global weight-loss solutions leader, announced today that it has entered into a definitive merger agreement with Obalon Therapeutics, Inc., which is listed on the NASDAQ Capital Market, a company focused on developing and commercializing novel technologies for weight loss, under which ReShape and Obalon will combine in an all-stock transaction.
Under the terms of the merger agreement that has been unanimously approved by the boards of directors of both companies, existing ReShape stockholders will have majority ownership of the combined company immediately following the closing of the merger and Obalon will be renamed ReShape Lifesciences Inc. and will trade under the NASDAQ ticker symbol "RSLS." The current directors and officers of ReShape will comprise the board of directors and executive management of the combined company.

California , United-states , Avenida-encinas , James-salierno , Calle-amanecer , Thomas-stankovich , Ruth-group , Obalon-therapeutics-inc , World-health-organization , Nasdaq , Exchange-commission , Maxim-group

Number of Shares and Voting Rights of ADOCIA as of December 31, 2020

Number of Shares and Voting Rights of ADOCIA as of December 31, 2020
Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French Code de Commerce and article 223-16 of the French stock-market authorities (
Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA, a French
société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Paris:ADOC) (Euronext Paris: FR0011184241 ADOC) a clinical stage biopharmaceutical company focused on diabetes treatment with innovative formulations of approved proteins, releases its total number of outstanding shares as well as its voting rights as of December 31, 2020.
Month
9 763 237
(1) The total number of theoretical voting rights (or "gross" voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.

Lacassagne , Midi-pyrees , France , Paris , France-general , French , Pramlintide-biochaperone-lispram , Biochaperone-aspram , James-salierno , Liraglutide-biochaperone , Raimund-gabriel , Mc-services

Adocia Announces Half Year Report on Adocia's Liquidity Agreement With Kepler Capital Markets

Adocia Announces Half Year Report on Adocia's Liquidity Agreement With Kepler Capital Markets
Regulatory News:
Under the liquidity agreement entrusted by Adocia (Paris:ADOC) to Kepler Capital Markets, the following resources were listed on the liquidity account
on
- Number of executions on sell side on semester: 355
- Traded volume on buy side on semester: 45,143 shares for 353,656.52
- Traded volume on sell side on semester: 47,151 shares for 374,968.20
As a reminder:
on June 30, 2020 on the liquidity account:
32,541 shares
15,026 shares
- 300,000.00
The liquidity agreement complies with AMF Decision n° 2018-01 dated 2nd July 2018, introducing liquidity agreements on equity securities as permitted market practice

Pramlintide-biochaperone-lispram , Biochaperone-aspram , James-salierno , Liraglutide-biochaperone , Raimund-gabriel , Mc-services , Ruth-group , Adocia-press-relations-europe , Regulatory-news , Kepler-capital-markets , Biochaperone-lispram , Reference-document